Viktoria Blumenberg

Viktoria Blumenberg

Auto-generated profile, based on publicly available information

Viktoria Blumenberg

Massachusetts General Hospital 1 Charlestown, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Blood
Verified
Journal Article
Open access
PDF file
KRKai Rejeski
Kai Rejeski
APAriel Perez
Ariel Perez
PSPierre Sesques
Pierre Sesques
EHEva Hoster
Eva Hoster
CBCarolina Berger
Carolina Berger
Marion SubkleweMarion Subklewe
Marion Subklewe
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related adverse event and remains poorly understood. In this multicenter analysis, we studied patterns of hematopoietic reconstitution and evaluated potential predictive markers in 258 patients receiving axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for relapsed/refractory large B-cell lymphoma. We observed profound (absolute neutrophil count [ANC] <100 cells per µL) neutropenia in 72% of patients and prolonged (21 days or longer) neutropenia in 64% of patients. The median duration of severe neutropenia (ANC < 500 cells per µL) was 9 days. We aimed to identify predictive biomarkers of hematotoxicity using the duration of severe neutropenia until day +60 as the primary end point. In the training cohort (n = 58), we observed a significant correlation with baseline thrombocytopenia (r = −0.43; P = .001) and hyperferritinemia (r = 0.54; P < .0001) on univariate and multivariate analysis. Incidence and severity of cytokine-release syndrome, immune effector cell–associated neurotoxicity syndrome, and peak cytokine levels were not associated with the primary end point. We created the CAR-HEMATOTOX model, which included markers associated with hematopoietic reserve (eg, platelet count, hemoglobin, and ANC) and baseline inflammation (eg, C-reactive protein and ferritin). This model was validated in independent cohorts, one from Europe (n = 91) and one from the United States (n = 109) and discriminated patients with severe neutropenia ≥14 days to <14 days (pooled validation: area under the curve, 0.89; sensitivity, 89%; specificity, 68%). A high CAR-HEMATOTOX score resulted in a longer duration of neutropenia (12 vs 5.5 days; P < .001) and a higher incidence of severe thrombocytopenia (87% vs 34%; P < .001) and anemia (96% vs 40%; P < .001). The score implicates bone marrow reserve and inflammation prior to CAR T-cell therapy as key features associated with delayed cytopenia and will be useful for risk-adapted management of hematotoxicity.

13 March 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CSChristoph K. Stein-Thoeringer
Christoph K. Stein-Thoeringer
NSNeeraj Y. Saini
Neeraj Y. Saini
EZEli Zamir
Eli Zamir
VBViktoria Blumenberg
Viktoria Blumenberg
MSMaria-Luisa Schubert
Maria-Luisa Schubert
Eran ElinavEran Elinav
Eran Elinav

3 June 2021 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
SLStefanie Lesch
Stefanie Lesch
VBViktoria Blumenberg
Viktoria Blumenberg
SSStefan Stoiber
Stefan Stoiber
AGAdrian Gottschlich
Adrian Gottschlich
JOJustyna Ogonek
Justyna Ogonek
SKSebastian Kobold
Sebastian Kobold

10 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GIGloria Iacoboni
Gloria Iacoboni
VGVictor Navarro Garcés
Victor Navarro Garcés
AMAna África Martín-López
Ana África Martín-López
KRKai Rejeski
Kai Rejeski
MKmi kwon
mi kwon
PBPere Barba
Pere Barba
PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3+ cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.

20 February 2025 in Blood
Verified
Journal Article
Closed access
RPRishika Prasad
Rishika Prasad
ARAbdur Rehman
Abdur Rehman
LRLubna Rehman
Lubna Rehman
FDFaezeh Darbaniyan
Faezeh Darbaniyan
VBViktoria Blumenberg
Viktoria Blumenberg
NSNeeraj Y. Saini
Neeraj Y. Saini
Antibiotic (ABX)–induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In this study, we observed that prior exposure to broad-spectrum ABXs with extended anaerobic coverage such as piperacillin-tazobactam and meropenem was associated with worse anti-CD19 CAR-T therapy survival outcomes in patients with large B-cell lymphoma (N = 422) than other ABX classes. In a discovery subset of these patients (n = 67), we found that the use of these ABXs was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n = 58). Broader evaluation of circulating microbial metabolites revealed reductions in indole and cresol derivatives, as well as trimethylamine N-oxide, in patients who received ABX treatment (discovery, n = 40; validation, n = 28). These findings were recapitulated in an immune-competent CAR-T mouse model, in which meropenem-induced dysbiosis led to a systemic dysmetabolome and decreased murine anti-CD19 CAR-T efficacy. Furthermore, we demonstrate that SCFAs can enhance the metabolic fitness of CAR-Ts, leading to improved tumor killing capacity. Together, these results suggest that broad-spectrum ABX deplete metabolically active commensals whose metabolites are essential for enhancing CAR-T efficacy, shedding light on the intricate relationship between ABX exposure, microbiome function and their impact on CAR-T efficacy. This highlights the potential for modulating the microbiome to augment CAR-T immunotherapy. This trial was registered at www.clinicaltrials.gov as #NCT06218602.

16 August 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
KRKai Rejeski
Kai Rejeski
ABAndreas Burchert
Andreas Burchert
GIGloria Iacoboni
Gloria Iacoboni
PSPierre Sesques
Pierre Sesques
LFLars Fransecky
Lars Fransecky
Marion SubkleweMarion Subklewe
Marion Subklewe
Key Points. Stem cell boost for persistent cytopenia after CD19 CAR-T is safe and clinically feasible resulting in high overall engraftment rates.Successful eng